Condition: Non-Small Cell Lung Cancer · Sponsor: Anhui Provincial Cancer Hospital
This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.
This description comes directly from the study's public registry record.
Shuanghu Yuan, PhD · 0551-62894008 · yuanshuanghu@sina.com
Li Li, PhD · 0551-62894008 · lililyde@163.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195084